Most employers think about drug use as a safety problem, and it is. But it is also a quiet, ongoing cost that rarely gets attributed to its real source. Understanding where that money goes is the first step to seeing why a modest investment in screening tends to pay for itself.

The costs you can see

Some effects are obvious once you look for them. National research bodies such as SAMHSA have long documented that workers with untreated substance use disorders miss more workdays and change jobs more often than their peers. For an employer, that translates directly into:

Absenteeism: unplanned days off that leave shifts short and coworkers covering.
Turnover: the cost of recruiting, onboarding, and training a replacement is significant for any role, and it repeats every time.
Accidents and workers' comp: impairment raises the odds of an on-the-job injury, and post-incident claims are expensive and slow.

The costs you cannot see on a report

The larger drain is often invisible. Reduced productivity — sometimes called presenteeism — is the employee who shows up but works at a fraction of their capacity. There is also the ripple effect on morale: reliable team members burn out when they repeatedly cover for someone who is not pulling their weight, and good people eventually leave. None of this appears as a line item, which is exactly why it goes unmanaged for so long.

What screening actually changes

A screening program does two things. First, it deters: a known, consistently applied testing policy discourages use among current and prospective employees, and it steers people who use toward roles or employers without testing. Second, it identifies risk early, before it becomes an accident, a claim, or a lawsuit.

The deterrent effect is the part employers underestimate. You are not trying to catch as many people as possible — you are trying to change behavior so there is less to catch. A pre-employment screen alone filters risk at the door, and a random program keeps the incentive in place year-round.

There is also a cultural return that rarely gets measured. When your reliable employees see that the standard applies to everyone, morale and retention improve — the people who show up and do the work stop feeling like they are quietly subsidizing someone who does not. That is real value, even though it never appears as a number on an invoice.

Running the simple math

You do not need fabricated statistics to make the case. Compare the cost of a single screen — typically a small, predictable per-test fee — against the fully loaded cost of one avoidable event: one preventable injury, one workers' comp claim, one bad hire who turns over in ninety days. It usually takes preventing only a handful of these events across a year for a screening program to more than cover itself. For most employers, the break-even is not close; screening is the cheaper side of the ledger by a wide margin.

Keeping the program affordable

The trick is to keep per-test costs low and administration simple so the program does not create its own overhead. That is where volume-friendly pricing and streamlined ordering matter. With LabX Diagnostic Systems, employers can open an employer account, buy screening in the quantities that fit their headcount, and manage results in a single secure portal — no per-visit clinic markups, no guesswork. If you want to see how the panels and pricing work, start with our testing overview.

The takeaway

Workplace drug use is not just a safety line item — it is absenteeism, turnover, accidents, and lost output compounding quietly all year. Affordable, consistent screening is one of the few interventions that reduces cost and risk at the same time. Want to see the numbers for your team? Set up an employer screening program with LabX.

The Real Cost of Workplace Drug Use (And How Affordable Screening Pays for Itself)